Duration of treatment

[1]  E. Akl,et al.  Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. , 2013, Blood.

[2]  J. Connors.  Extended treatment of venous thromboembolism. , 2013, The New England journal of medicine.

[3]  G. Raskob,et al.  Apixaban for extended treatment of venous thromboembolism. , 2013, The New England journal of medicine.

[4]  M. Prins,et al.  International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer , 2013, Journal of thrombosis and haemostasis : JTH.

[5]  A. Khorana,et al.  International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer , 2013, Journal of thrombosis and haemostasis : JTH.

[6]  J. Douketis,et al.  Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH , 2012, Journal of Thrombosis and Haemostasis.

[7]  C. Kearon,et al.  A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism , 2012, Journal of thrombosis and haemostasis : JTH.

[8]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[9]  G. Stansby,et al.  The management of venous thromboembolic diseases and the role of thrombophilia testing: summary of NICE Guideline CG144. , 2012, Acute medicine.

[10]  Giancarlo Agnelli,et al.  Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials , 2011, BMJ : British Medical Journal.

[11]  Mary Cushman,et al.  Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis , 2011, BMJ : British Medical Journal.

[12]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[13]  J. Douketis,et al.  Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient‐level meta‐analysis , 2010, Journal of thrombosis and haemostasis : JTH.

[14]  A. Iorio,et al.  Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. , 2010, Archives of internal medicine.

[15]  J. Douketis,et al.  Patient-Level Meta-analysis: Effect of Measurement Timing, Threshold, and Patient Age on Ability of d-Dimer Testing to Assess Recurrence Risk After Unprovoked Venous Thromboembolism , 2010, Annals of Internal Medicine.

[16]  G. Mariani,et al.  Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. , 2008, Blood.

[17]  D. P. Bentley,et al.  Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial , 2007, BMJ : British Medical Journal.

[18]  A. Iorio,et al.  D-dimer testing to determine the duration of anticoagulation therapy. , 2006, The New England journal of medicine.

[19]  Frits R Rosendaal,et al.  Thrombophilia, clinical factors, and recurrent venous thrombotic events. , 2005, JAMA.

[20]  R. Farraj.  Anticoagulation period in idiopathic venous thromboembolism. How long is enough? , 2004, Saudi medical journal.

[21]  S. Schulman,et al.  Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. , 2003, The New England journal of medicine.

[22]  T. Baglin,et al.  Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study , 2003, The Lancet.

[23]  W. Ageno,et al.  Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism , 2003, Annals of Internal Medicine.

[24]  P. Ridker,et al.  Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.

[25]  Paolo Prandoni,et al.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.

[26]  P. Romano,et al.  Comparison of Outcomes after Hospitalization for Deep Venous Thrombosis or Pulmonary Embolism , 2002, Thrombosis and Haemostasis.

[27]  P. Prandoni,et al.  Three months vs. one year of oral anticoagulant therapy for idiopathic deep venous thrombosis , 2002 .

[28]  B. Cosmi,et al.  Risk of Venous Thromboembolism Recurrence: High Negative Predictive Value of D-dimer Performed after Oral Anticoagulation Is Stopped , 2002, Thrombosis and Haemostasis.

[29]  I. Durieu,et al.  Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis , 2001, Circulation.

[30]  J. Hirsh,et al.  A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy , 2000, Thrombosis and Haemostasis.

[31]  H. Eriksson,et al.  Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. , 2000, Archives of internal medicine.

[32]  L. Melton,et al.  Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. , 2000, Archives of internal medicine.

[33]  M Gent,et al.  A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.

[34]  O. Linder,et al.  The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. , 1997, The New England journal of medicine.

[35]  Paolo Prandoni,et al.  The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[36]  M. Gent,et al.  Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis , 1995, Thrombosis and Haemostasis.

[37]  Olle Linder,et al.  A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism , 1995 .

[38]  K. Schulman,et al.  Cost-effectiveness analyses. , 1995, The New England journal of medicine.

[39]  M. Pini,et al.  Low Molecular Weight Heparin versus Warfarin in the Prevention of Recurrences after Deep Vein Thrombosis , 1994, Thrombosis and Haemostasis.

[40]  Researchcommitteeofthebritish.  Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism*1 , 1992 .